{
    "startDate": "2021-01-01",
    "endDate": "2021-03-31",
    "year": "2021",
    "quarter": "Q1",
    "symbol": "LIFE",
    "data": {
        "bs": [
            {
                "label": "Cash and cash equivalents",
                "concept": "CashAndCashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 12587000
            },
            {
                "label": "Available-for-sale investments",
                "concept": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
                "unit": "usd",
                "value": 38050000
            },
            {
                "label": "Other receivables",
                "concept": "OtherReceivablesNetCurrent",
                "unit": "usd",
                "value": 89000
            },
            {
                "label": "Prepaid expenses",
                "concept": "PrepaidExpenseCurrent",
                "unit": "usd",
                "value": 1408000
            },
            {
                "label": "Current assets:",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 52134000
            },
            {
                "label": "Property and equipment, net",
                "concept": "PropertyPlantAndEquipmentNet",
                "unit": "usd",
                "value": 874000
            },
            {
                "label": "Right-of-use assets",
                "concept": "OperatingLeaseRightOfUseAsset",
                "unit": "usd",
                "value": 1886000
            },
            {
                "label": "Other assets",
                "concept": "OtherAssetsNoncurrent",
                "unit": "usd",
                "value": 234000
            },
            {
                "label": "Assets",
                "concept": "Assets",
                "unit": "usd",
                "value": 55128000
            },
            {
                "label": "Accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 1161000
            },
            {
                "label": "Accrued expenses",
                "concept": "AccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 2400000
            },
            {
                "label": "Current portion of operating lease liability",
                "concept": "OperatingLeaseLiabilityCurrent",
                "unit": "usd",
                "value": 890000
            },
            {
                "label": "Current liabilities:",
                "concept": "LiabilitiesCurrent",
                "unit": "usd",
                "value": 4451000
            },
            {
                "label": "Long-term operating lease liability, net of current portion",
                "concept": "OperatingLeaseLiabilityNoncurrent",
                "unit": "usd",
                "value": 1145000
            },
            {
                "label": "Commitments and contingencies (Note 4)",
                "concept": "CommitmentsAndContingencies",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares; Class X Convertible Preferred Stock issued and outstanding shares \u2013 0 as of March 31, 2021 (unaudited) and December 31, 2020, respectively",
                "concept": "PreferredStockValue",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Common stock, $0.001 par value per share; 21,425,000 authorized shares as of March 31, 2021 and December 31, 2020, respectively; issued and outstanding shares \u2013 16,011,385 (unaudited) and 11,018,954 as of March 31, 2021 and December 31, 2020, respectively",
                "concept": "CommonStockValue",
                "unit": "usd",
                "value": 16000
            },
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapital",
                "unit": "usd",
                "value": 395422000
            },
            {
                "label": "Accumulated other comprehensive loss",
                "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
                "unit": "usd",
                "value": -57000
            },
            {
                "label": "Accumulated deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -345679000
            },
            {
                "label": "Stockholders\u2019 equity:",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": 49702000
            },
            {
                "label": "Noncontrolling interest in Pangu BioPharma Limited",
                "concept": "MinorityInterest",
                "unit": "usd",
                "value": -170000
            },
            {
                "label": "Total stockholders' equity",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 49532000
            },
            {
                "label": "Liabilities and Stockholders\u2019 Equity",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 55128000
            }
        ],
        "cf": [
            {
                "label": "Consolidated net income (loss)",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -7155000
            },
            {
                "label": "Depreciation and amortization",
                "concept": "DepreciationDepletionAndAmortization",
                "unit": "usd",
                "value": 121000
            },
            {
                "label": "Stock-based compensation",
                "concept": "AllocatedShareBasedCompensationExpense",
                "unit": "usd",
                "value": 360000
            },
            {
                "label": "Amortization (accretion) of premium (discount) of available-for-sale investment securities",
                "concept": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
                "unit": "usd",
                "value": -51000
            },
            {
                "label": "Operating lease right of use asset amortization.",
                "concept": "life:OperatingLeaseRightOfUseAssetAmortization",
                "unit": "usd",
                "value": 176000
            },
            {
                "label": "Other receivables",
                "concept": "IncreaseDecreaseInOtherReceivables",
                "unit": "usd",
                "value": -1950000
            },
            {
                "label": "Prepaid expenses and other assets",
                "concept": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
                "unit": "usd",
                "value": -395000
            },
            {
                "label": "Accounts payable and accrued expenses",
                "concept": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
                "unit": "usd",
                "value": -1521000
            },
            {
                "label": "Increase (decrease) in operating lease liability.",
                "concept": "life:IncreaseDecreaseInOperatingLeaseLiability",
                "unit": "usd",
                "value": -204000
            },
            {
                "label": "Cash flows from operating activities:",
                "concept": "NetCashProvidedByUsedInOperatingActivities",
                "unit": "usd",
                "value": -5827000
            },
            {
                "label": "Purchases of property and equipment",
                "concept": "PaymentsToAcquirePropertyPlantAndEquipment",
                "unit": "usd",
                "value": 17000
            },
            {
                "label": "Purchases of available-for-sale investment securities",
                "concept": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
                "unit": "usd",
                "value": 25678000
            },
            {
                "label": "Maturities of available-for-sale investment securities",
                "concept": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
                "unit": "usd",
                "value": 2300000
            },
            {
                "label": "Cash flows from investing activities:",
                "concept": "NetCashProvidedByUsedInInvestingActivities",
                "unit": "usd",
                "value": -23395000
            },
            {
                "label": "Proceeds from issuance of common stock through at market offering net of offering costs.",
                "concept": "life:ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts",
                "unit": "usd",
                "value": 9621000
            },
            {
                "label": "Proceeds from issuance of common stock through registered direct offering, net of offering costs.",
                "concept": "life:ProceedsFromIssuanceOfCommonStockThroughRegisteredDirectOfferingNetOfOfferingCosts",
                "unit": "usd",
                "value": 15236000
            },
            {
                "label": "Cash flows from financing activities:",
                "concept": "NetCashProvidedByUsedInFinancingActivities",
                "unit": "usd",
                "value": 24857000
            },
            {
                "label": "Net change in cash and cash equivalents",
                "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
                "unit": "usd",
                "value": -4365000
            }
        ],
        "ic": [
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 4516000
            },
            {
                "label": "General and administrative",
                "concept": "GeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 2686000
            },
            {
                "label": "Operating expenses:",
                "concept": "OperatingExpenses",
                "unit": "usd",
                "value": 7202000
            },
            {
                "label": "Income (loss) from operations",
                "concept": "OperatingIncomeLoss",
                "unit": "usd",
                "value": -7202000
            },
            {
                "label": "Total other income (expense), net",
                "concept": "NonoperatingIncomeExpense",
                "unit": "usd",
                "value": 47000
            },
            {
                "label": "Consolidated net income (loss)",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -7155000
            },
            {
                "label": "Net loss attributable to noncontrolling interest in Pangu BioPharma Limited",
                "concept": "NetIncomeLossAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -4000
            },
            {
                "label": "Net loss attributable to noncontrolling interest in Pangu BioPharma Limited",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -7151000
            },
            {
                "label": "Basic, net income (loss) per share",
                "concept": "EarningsPerShareBasic",
                "unit": "usd/shares",
                "value": -0.51
            },
            {
                "label": "Shares used in computing basic net income (loss) per share",
                "concept": "WeightedAverageNumberOfSharesOutstandingBasic",
                "unit": "shares",
                "value": 14103783
            },
            {
                "label": "Diluted net income (loss) per share",
                "concept": "EarningsPerShareDiluted",
                "unit": "usd/shares",
                "value": -0.51
            },
            {
                "label": "Shares used in computing diluted net income (loss) per share",
                "concept": "WeightedAverageNumberOfDilutedSharesOutstanding",
                "unit": "shares",
                "value": 14103783
            },
            {
                "label": "Change in unrealized loss on available-for-sale investments, net of tax",
                "concept": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
                "unit": "usd",
                "value": -14000
            },
            {
                "label": "Comprehensive income (loss)",
                "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -7169000
            },
            {
                "label": "Comprehensive loss attributable to noncontrolling interest Pangu BioPharma Limited",
                "concept": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -4000
            },
            {
                "label": "Comprehensive income (loss)",
                "concept": "ComprehensiveIncomeNetOfTax",
                "unit": "usd",
                "value": -7165000
            }
        ]
    }
}